Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering

Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS

Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (ADSs) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase... More

Jones Trading Upgrades Adaptimmune Therapeutics plc (ADAP) to Buy

Jones Trading analyst Soumit Roy upgraded Adaptimmune Therapeutics plc (NASDAQ: ADAP) from Hold to Buy.

For an analyst ratings summary and ratings history on Adaptimmune Therapeutics plc click here. For more ratings news on Adaptimmune Therapeutics plc click here.

Shares of Adaptimmune Therapeutics plc closed at $4.86 yesterday.

Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'

Mizuho Securities analyst Mara Goldstein reiterated a Neutral rating and $3.00 price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP), but said ASCO data was "incrementally supportive, acceleration of Synovial Sarcoma trial."

The analyst commented, "ADAP reported a substantial data update this morning via... More

Adaptimmune (ADAP) Announces SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction, Lung, and Head and Neck Cancers

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting. The data demonstrate durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial. The ASCO presentation also describes a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).

The Company also announced new responses in the SURPASS trial, confirming the potential for... More